Bonnie Seecharran, MD
Cardiovascular Disease · Middletown, NYNPI 1891796645
Payments from drug & device makers
Across 444 payments — averaging $303.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$53K
- Amarin Pharma, Inc.$23K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$18K
- Novartis$18K
- Johnson & Johnson$12K
- Lundbeck LLC$3K
- plus $7K from 25 others
What the payments were for
- Consulting fees$2,8502%
- Speaking & faculty fees$116,34186%
- Travel & lodging$5,6634%
- Food & beverage$9,7127%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 79 | $53,383 |
| Amarin Pharma, Inc. | 45 | $23,045 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 54 | $18,249 |
| Novartis | 49 | $17,872 |
| Johnson & Johnson | 22 | $11,781 |
| Lundbeck LLC | 11 | $3,064 |
| Pfizer | 15 | $2,393 |
| E.r. Squibb & Sons, L.L.C. | 8 | $1,336 |
| Abbott | 6 | $539 |
| Boehringer Ingelheim | 23 | $507 |
| Merck | 29 | $454 |
| Sanofi-aventis U.S. LLC | 14 | $313 |
| AstraZeneca | 21 | $296 |
| Kowa Pharmaceuticals America, Inc. | 18 | $266 |
| Regeneron Healthcare Solutions, Inc. | 9 | $166 |
| Abiomed | 1 | $150 |
| Bayer | 4 | $104 |
| Lexicon Pharmaceuticals, Inc. | 5 | $102 |
| Esperion Therapeutics, Inc. | 6 | $98 |
| Sanofi | 3 | $97 |
| Philips North America LLC | 4 | $72 |
| Arbor Pharmaceuticals, Inc. | 5 | $65 |
| Alnylam Pharmaceuticals Inc. | 3 | $61 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Astellas Pharma US Inc | 2 | $38 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$52,377
- Vascepa$22,337
- LifeVest$17,741
- ENTRESTO$16,059
- XARELTO$11,474
- ELIQUIS$3,300
- NORTHERA$2,850
- LEQVIO$1,188
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$176
- HeartMate 3 Left Ventricular Dev$163
- Impella$150
- HeartMate 3 Left Ventricular Assist Device$119
How this compares
$134,588 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 274 | $359,287 |
| EntrestoSacubitril/Valsartan | 176 | $255,978 |
| Repatha SureclickEvolocumab | 67 | $89,026 |
| XareltoRivaroxaban | 70 | $81,755 |
| BrilintaTicagrelor | 59 | $64,884 |
| MultaqDronedarone Hcl | 35 | $61,664 |
| FarxigaDapagliflozin Propanediol | 49 | $59,607 |
| JardianceEmpagliflozin | 39 | $51,816 |
| Praluent PenAlirocumab | 36 | $33,524 |
| Repatha SyringeEvolocumab | 33 | $32,920 |
| NexlizetBempedoic Acid/Ezetimibe | 38 | $31,433 |
| VascepaIcosapent Ethyl | 38 | $28,729 |
| NexletolBempedoic Acid | 38 | $24,844 |
| Icosapent Ethyl | 61 | $22,816 |
| Repatha PushtronexEvolocumab | 14 | $18,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,393 | $359,287274 claims |
| NovartisEntresto | $17,872 | $255,978176 claims |
| AstraZenecaBrilinta, Farxiga | $296 | $124,491108 claims |
| Johnson & JohnsonXarelto | $11,781 | $81,75570 claims |
| Sanofi-aventis U.S. LLCMultaq | $313 | $61,66435 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $98 | $56,27676 claims |
| Boehringer IngelheimJardiance | $507 | $51,81639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Middletown
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.